Richard R Jin

US Patent:

20100298200, Nov 25, 2010

Filed:

May 22, 2009

Appl. No.:

12/454765

Inventors:

Dakai Liu - South Setauket NY, US
Xiaofeng Li - Farmington CT, US
Richard Jin - Pennington NJ, US
Wei Cheng - Seaford NY, US
Riddhi Bhattacharyya - West Babylon NY, US
Guangrong Zhang - Shrewsburry MA, US

International Classification:

A61K 38/02
C07D 265/38
C07C 309/53
C07C 235/56
C07D 251/70
C07C 229/66
A61K 31/538
A61K 31/196
A61K 31/185
A61K 31/277
A61K 31/53
A61K 31/245
A61K 31/366
A61K 31/12
A61K 31/165
A61K 31/167
A61K 31/505
A61K 31/122
A61K 31/235
A61K 31/05
A61K 31/365
A61K 31/343
A61P 31/12
A61P 25/00
A61P 19/00
A61P 35/00
A61P 3/08
A61P 3/06
G01N 33/00
C12Q 1/02
C12Q 1/68
G01N 33/53
G01N 33/542
C40B 30/04
C40B 30/02
C12N 5/10
C12Q 1/66

US Classification:

514 11, 544102, 562 46, 562 55, 558427, 562455, 544197, 560 48, 5142298, 514562, 514577, 514523, 514563, 514245, 514510, 514450, 514685, 514614, 514256, 514275, 514524, 514680, 514544, 514734, 514468, 800 3, 435 29, 435 6, 435 71, 435 79, 506 9, 506 8, 435325, 435 8

Abstract:

The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.

US Patent:

20110105606, May 5, 2011

Filed:

Aug 7, 2008

Appl. No.:

12/221863

Inventors:

Elazar Rabbani - New York NY, US
Xiaofeng Li - Farmington NY, US
Dakai Liu - South Setauket NY, US
Yazhou Zhang - South Setauket NY, US
Richard Jin - Pennington NJ, US
Riddhi Bhattacharyya - West Babylon NY, US
Wei Cheng - Valley Stream NY, US
James J. Donegan - Long Beach NY, US

International Classification:

A61K 31/235
A61P 3/06
A61P 29/00
A61P 37/02
A61P 3/08
A61P 17/14
A61K 31/192
A61K 31/185
C40B 30/06
C40B 30/02
C40B 30/04

US Classification:

514533, 514568, 514577, 506 10, 506 8, 506 9

Abstract:

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

US Patent:

20130034866, Feb 7, 2013

Filed:

Jul 24, 2012

Appl. No.:

13/556425

Inventors:

JACK COLEMAN - EAST NORTHPORT NY, US
MACIEJ SCZEPANIK - MOUNT SINAI NY, US
RICHARD JIN - PENNINGTON NJ, US

International Classification:

G01N 33/53
C07K 17/08
G01N 21/76

US Classification:

435 79, 436501, 5303913

Abstract:

Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

US Patent:

20140030787, Jan 30, 2014

Filed:

Jul 24, 2012

Appl. No.:

13/556304

Inventors:

JACK COLEMAN - EAST NORTHPORT NY, US
MACIEJ SZCZEPANIK - MOUNT SINAI NY, US
RICHARD JIN - PENNINGTON NJ, US

International Classification:

C12N 11/02
C07K 14/36
C07H 21/04

US Classification:

435177, 536 231, 530358

Abstract:

Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

US Patent:

20100041599, Feb 18, 2010

Filed:

Aug 15, 2008

Appl. No.:

12/228757

Inventors:

Dakai Liu - South Setauket NY, US
Richard Jin - Pennington NJ, US
Xiaofeng Li - Farmington CT, US
Yazhou Zhang - South Setauket NY, US
Wei Cheng - Valley Stream NY, US
Riddhi Bhattacharyya - West Babylon NY, US

International Classification:

A61K 38/22
C12Q 1/68
A61P 19/08

US Classification:

514 12, 435 6

Abstract:

The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on Wnt activity, through the use of in vitro experiments involving cells that have in at least one gene mutation involved in the Wnt pathway.

US Patent:

20210325375, Oct 21, 2021

Filed:

Jun 17, 2021

Appl. No.:

17/349970

Inventors:

- Farmingdale NY, US
Maciej Szczepanik - Mount Sinai NY, US
Richard Jin - Pennington NJ, US

Assignee:

Enzo Life Science, Inc. - Farmingdale NY

International Classification:

G01N 33/53
C07H 21/00
C07H 21/04
C09B 11/08
C09B 11/24
C12Q 1/6818
G01N 33/58
G01N 33/82
G01N 33/94

Abstract:

Provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.

US Patent:

20200360392, Nov 19, 2020

Filed:

Apr 21, 2020

Appl. No.:

16/853792

Inventors:

- Farmingdale NY, US
Xiaofeng Li - Farmington CT, US
Dakai Liu - South Setauket NY, US
Yazhou Zhang - South Setauket NY, US
Richard Jin - Pennington NJ, US
Riddhi Bhattacharyya - West Babylon NY, US
Wei Cheng - Valley Stream NY, US
James J. Donegan - Amesbury MA, US

Assignee:

ENZO BIOCHEM, INC - Farmingdale NY

International Classification:

A61K 31/538
A61K 31/535
A61K 31/015
A61K 31/395
G01N 33/50
G01N 33/564
G01N 33/92
A61K 31/185
A61K 31/192
A61K 31/235
A61P 3/10

Abstract:

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

US Patent:

20200284786, Sep 10, 2020

Filed:

Mar 9, 2020

Appl. No.:

16/812769

Inventors:

- Farmingdale NY, US
Maciej Szczepanik - Mount Sinai NY, US
Richard Jin - Pennington NJ, US

Assignee:

Enzo Life Science, Inc. - Farmingdale NY

International Classification:

G01N 33/543
G01N 33/58
C12Q 1/68

Abstract:

Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.